Loophole in Patent Law Brings ‘Miracle Drug’ to Patients Who Can’t Afford It
Beximco Pharma has initiated the supply of a low-cost cystic fibrosis medication to patients across six countries following a patent law loophole.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Beximco Pharma has begun distributing a generic version of a cystic fibrosis treatment, branded as TRIKO, to patients in six countries. This initiative provides a lower-cost alternative for individuals unable to access existing, higher-priced therapies. The distribution is characterized as a response to specific gaps within current patent law regulations.
Coverage from The New York Times, TipRanks, Newagebd.net, The Business Standard, and daily-sun.com highlights the drug's affordability and the legal mechanism enabling its release. Reports emphasize that the first patients have already received the therapy, marking the start of the supply program. Future developments will depend on the continued availability of the medication and any potential regulatory or legal responses regarding the use of the patent loophole.
Coverage does not yet specify which countries are included in the distribution or the long-term impact on global access to the therapy.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 148d ago.
Quick answers
What is the name of the new medication?
The medication is referred to as TRIKO.
How is Beximco Pharma able to offer this drug at a lower cost?
Coverage indicates the company is utilizing a loophole in patent law.
Which countries are receiving the medicine?
Coverage confirms that patients from six countries are included, though specific names of the countries have not been released.
Coverage (6)
- Beximco Pharma hands over low-cost generic cystic fibrosis drug to patients The Business Standard · 149d ago
- Beximco Pharma hands over affordable CF medicines to patients from six countries daily-sun.com · 149d ago
- Beximco Pharma starts supplying low-cost cystic fibrosis medicine Newagebd.net · 149d ago
- affordable medicine The Business Standard · 149d ago
- Beximco launches cut‑price cystic fibrosis therapy as first patients receive TRIKO TipRanks · 149d ago
- Loophole in Patent Law Brings ‘Miracle Drug’ to Patients Who Can’t Afford It The New York Times · 149d ago
Topics
Related trends
The first pill to slow Alzheimer’s could come from an unexpected place
An experimental oral Alzheimer's drug derived from an unexpected medical category shows varied results in phase 3 clinical trials.
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
Novo Nordisk raises its 2026 outlook and shares surge as the Wegovy weight-loss pill rollout accelerates.